anti-IL-23 receptor antibody fragment (Numab)

N/A

Report date: 2025/03/14 16:48:57

Base Information

Drug Nameanti-IL-23 receptor antibody fragment (Numab)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionInterleukin 23 Receptor modulators
TargetsInterleukin 23 Receptor
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNumab Therapeutics Ag
China Registration ClassN/A

Develop Information

Active CompaniesNumab Therapeutics Ag
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A